Sage Therapeutics SAGE 深 沪
已收盘 07-31 16:00:00 美东时间
8.68
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.68
- 总市值 5.44亿
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.62
- 委 比 0.00%
- 总股本 6262.23万
- 历史最高 195.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.62
- 每 手 1
- 风险率 1.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus a new buy at BofA on 'underappreciated' CNS assets
BofA Securities has initiated coverage of Supernus Pharmaceuticals (SUPN) at buy saying that the market is not fully appreciating the company's portfolio of central nervous system drugs. The bank set ...
10-30 02:37
Reported Sunday, Leonardo DRS Launches SAGEcore Ruggedized AI Software Platform For Real-Time Threat Detection And Decision Support At The Tactical Edge
Software platform uses AI and machine learning for rapid fusing of complex data into shared, real-time view of battlespace for faster, smarter and safer action under fire
10-13 14:38
Century Communities to host September Grand Opening in Riverside, CA
New Neighborhood Brings Fresh Energy and Stylish Townhomes to the Heart of the Inland Empire RIVERSIDE, Calif., Sept. 25, 2025 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS)—a top nat...
09-26 04:26
FleishmanHillard Appoints New Global Corporate Affairs Leadership
New leadership strengthens integration across regions and capabilities, helping clients navigate uncertainty, reputation, risk and transformation at speed NEW YORK, Aug. 7, 2025 /PRNewswire/...
08-07 19:30
Supernus Pharmaceuticals Clears Antitrust Hurdle For Sage Therapeutics Acquisition In $8.50/Share Cash Offer Plus Up To $3.50/Share In Contingent Value Rights Merger
Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supern
07-28 20:27
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
07-28 12:25
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
07-25 21:23
华硕TRX50主板首秀 多款ProArt、WS主板赋能BIRTV2025
【7/23/2025,新闻稿，共6页】 华硕TRX50主板首秀多款ProArt、WS主板赋能BIRTV2025备选：算力重构视界华硕主板惊艳BIRTV2025...
07-24 17:39
